<p><strong>Elderly</strong>: No dose adjustment is necessary for elderly patients (&gt; 65 years). There are limited clinical data in patients aged 75 or over.<br />
<br />
<strong>Paediatric population</strong>: The safety and efficacy of niraparib in children and adolescents below 18 years of age have not yet been established. No data are available.<br />
<br />
<strong>Renal impairment</strong>: No dose adjustment is necessary for patients with mild to moderate renal impairment. There are no data in patients with severe renal impairment or end-stage renal disease undergoing hemodialysis; use with caution in these patients.<br />
<br />
<strong>Hepatic impairment</strong>: No dose adjustment is needed in patients with mild to moderate hepatic impairment. There are no data in patients with severe hepatic impairment; use with caution in these patients.</p>